PET/CT-guided percutaneous biopsy for diagnosis of MPNST in Neufibromatosis Type 1 (NF1).

P. Combemale(Centre Léon Bérard), Dominique Ranchère(Centre Léon Bérard), Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), Philippe Thiesse(Institut Gustave Roussy), Anne‐Valérie Decouvelaere(Centre Léon Bérard), S. Pinson(Hôpital Edouard Herriot), Mehdi Brahmi(Centre Léon Bérard), Jean‐Yves Blay(Université Claude Bernard Lyon 1)

Journal of Clinical Oncology

May 20, 2015

10.1200/jco.2015.33.15_suppl.e21513

Cited by 0

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

|The Lancet|2012|2.1k

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

|New England Journal of Medicine|2015|1.7k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

|The Lancet Oncology|2014|1.2k

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

|Annals of Oncology|2021|978